BioSpace

Summit snags $2B investment from AstraZeneca, clearing financial overhang

The all-stock deal gives Summit Therapeutics enough money to see through Phase 3 trials for the PD-1/VEGF bispecific ivonescimab—but keeps the asset fully in-house without giving up licensing rights.

By BioSpace

1 min read
Summit snags $2B investment from AstraZeneca, clearing financial overhang
Summit snags $2B investment from AstraZeneca, clearing financial overhang

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights